UF-021 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
90	Retinitis pigmentosa	3

90. Retinitis pigmentosa

---

Clinical trials : 130 /  Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01786395 (ClinicalTrials.gov)	March 2013	23/1/2013	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa	Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period	Retinitis Pigmentosa	Drug: UF-021;Drug: Placebo	R-Tech Ueno, Ltd.	NULL	Terminated	20 Years	70 Years	Both	202	Phase 3	Japan
2	JPRN-JapicCTI-090748	01/10/2008	20/04/2009	Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa	Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa	retinitis pigmentosa	Intervention name : UF-021 (isopropyl unoprostone) Dosage And administration of the intervention : Eye drop	R-Tech Ueno, Ltd	NULL		20	65	BOTH	105	Phase 2	NULL
3	JPRN-JapicCTI-132079			Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period	Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period	Retinitis Pigmentosa	Intervention name : UF-021(isopropyl unoprostone) Dosage And administration of the intervention : Eye drop Control intervention name : null	R-Tech Ueno, Ltd	NULL		20	70	BOTH		Phase 3	NULL